Amphotericin B-resistant Aspergillus flavus infection successfully treated with caspofungin, a novel antifungal agent.
Invasive aspergillosis is uncommon in immunocompetent hosts but is the second most common opportunistic fungal infection in immunocompromised patients. There has been a dramatic increase in the incidence of life-threatening aspergillosis during the past 2 decades, and the morbidity and mortality of these infections despite antifungal therapy remain unacceptably high. We describe a patient with amphotericin B-resistant Aspergillus flavus successfully treated with caspofungin, an agent belonging to a new class of antifungal drugs. Caspofungin shows great promise in the treatment of invasive aspergillosis.
Koss
Tamara
T
Department of Dermatology, Columbia-Presbyterian Medical Center, New York, New York, USA.
Bagheri
Bita
B
Zeana
Cosmina
C
Romagnoli
Mario F
MF
Grossman
Marc E
ME
D000368:Aged; D000666:Amphotericin B / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001132:Arm; D001228:Aspergillosis / Q000188:drug therapy* / Q000473:pathology; D001231:Aspergillus flavus / Q000187:drug effects* / Q000302:isolation & purification; D000077336:Caspofungin; D025141:Drug Resistance, Fungal; D054714:Echinocandins; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D055666:Lipopeptides; D010455:Peptides; D010456:Peptides, Cyclic
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D010455:Peptides; D010456:Peptides, Cyclic; D000666:Amphotericin B; D000077336:Caspofungin